Takeda Pharmaceutical Li... (TAK)
| Bid | 15.02 |
| Market Cap | 47.64B |
| Revenue (ttm) | 4,546.1B |
| Net Income (ttm) | 290B |
| EPS (ttm) | 0.46 |
| PE Ratio (ttm) | 32.66 |
| Forward PE | 0.34 |
| Analyst | n/a |
| Ask | 15.03 |
| Volume | 716,337 |
| Avg. Volume (20D) | 1,907,359 |
| Open | 15.20 |
| Previous Close | 15.29 |
| Day's Range | 15.01 - 15.20 |
| 52-Week Range | 12.58 - 15.37 |
| Beta | 0.34 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Reves...
20 hours ago · businesswire.com
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM EducationCAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
3 weeks ago · accessnewswire.com
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...
